Profiles
Bruce Lyons
Bruce Lyons
Adjunct Senior Researcher
Room 240 , Medical Science 2
The distressing facts about devil facial tumour disease (DFTD) have become well known in recent years, with the Tasmanian devil population declining by more than 80 per cent since this rare, transmissible cancer was first detected in the 1990s. Equally dramatic, however, has been the response to save this iconic marsupial.
DFTD vaccine: devil is in the detail
Dr Bruce Lyons, a senior lecturer in Immunology in the UTAS School of Medicine, is a leader of the group that is working on a vaccine to protect Tasmanian devils from this almost invariably-fatal cancer. The team has been able to produce in the laboratory an immune response in devils to DFTD, and also found that the devil’s immune system can, in certain circumstances, eradicate the tumours. The next step is to ‘connect the dots’ to hopefully produce a single-shot vaccine.
‘We’ve still got a bit of a way to get there,’ Dr Lyons said, ‘but compared to the history of tumour immunology in human work, the achievements with devils in the last 10 years are outstanding.’
Switching on the immune system
DFTD is passed from devil to devil through contact, such as the biting associated with mating and fighting. It produces large tumours, mostly around the face and neck, which lead to death from starvation and the breakdown of bodily functions.
While these tumours are confronting to witness, it is their ability to become invisible to the devil’s immune system that makes them so deadly. All transplanted tissue will normally be rejected as different by its host because of surface molecules called MHC, but the DFTD tumours have sneakily worked out a way to shut off these MHC molecules.
To counter this, scientists have developed methods to force the tumours to again produce these MHC molecules – and it was live cancer cells, treated to show MHC, that were used as the basis for immunotherapy by Dr Lyons and the DFTD immunology group.
‘When we injected those treated cells just next to the tumour, we found that the tumour would just melt away,’ Dr Lyons said. ‘In three out of the six devils, the tumour completely disappeared. So we know that the immune system can get rid of the tumour, and our current model of the immunisation candidate is also using DFTD cells that have been treated to express those MHC molecules.’
The challenge of the puzzle
Before returning to Tasmania and accepting a position at UTAS, Dr Lyons completed post-doctoral work in Scotland as well as at the John Curtin School of Medical Research in the ACT, and at the Institute of Medical and Veterinary Science in Adelaide. This was followed by industry work on the development of vaccines, providing a natural link not only to his research on the devil vaccine but also his other area of interest, which is the allergy to jack jumper ants.
‘Immunology was completely new as a standalone course when I began to study it as an undergraduate, and that really attracted me,’ Dr Lyons said. ‘Of course immunology as we know it has been practised since the late 1700s with the development of the smallpox vaccine, but it was all empirical – nobody had a clue how it worked. It was a detective story waiting to be investigated.
‘When I think back on the work we did in those early years of immunology in the mid ‘80s to early 2000s, I realise we got the chance to fill in some major holes in our understanding. I think that has been my driving force. This is probably true for many scientists in that it’s the puzzle that provides the challenge that keeps you going. It’s like being a detective in that we’re trying to figure out what’s going on. That investigative drive is what keeps us scientists plugging away.’
Dr Lyons is a senior lecturer in the School of Medicine. His career spans basic and applied immunology in the fields of leukaemia research, leukocyte trafficking, vaccine development and tumour immunology, with a particular interest in applied flow cytometry methodology.
Biography
Dr Lyons' PhD in Immunology from the University of Adelaide (1988) was on the development of monoclonal antibodies to human myeloid differentiation antigens. After a short period examining cytokine control of histamine release by basophils (Human Immunology, IMVS, Adelaide), his postdoctoral studies included apoptosis and chronic lymphocytic leukaemia models (University of Edinburgh), lymphocyte migration to spleen (JCSMR, ANU and University of Tasmania) and off-target immunological effects of new small molecule targeted therapies for chronic myeloid leukaemia (Haematology, IMVS Adelaide). After 2 years in a biotech start up investigating new carbohydrate adjuvants (Vaxine, Flinders University, Adelaide) Dr Lyons returned to the University of Tasmania to take up a teaching only senior lectureship in 2008, before being appointed to a teaching/research senior lectureship in 2010.
Career summary
Qualifications
- PhD, University of Adelaide, Australia, 1988. Human myeloid differentiation antigens
- BSc (Upper 2nd Class Hons), University of Adelaide, Australia, 1983. Preparation of membrane antigeens from normal and leukaemic cells
Memberships
Professional practice
- Australasian Society for Immunology
Administrative expertise
- Research project management
- Graduate research coordination
- Honours program coordination
- Management of a central flow cytometry and imaging facility
Teaching
Immunology, unit design (Immunology), flow cytometric applications
Teaching responsibility
View more on AssocProf Bruce Lyons in WARP
Expertise
- Specialised flow cytometric techniques to examine cell division, apoptosis and adhesion
- Small laboratory animal models of immune processes
- Monoclonal antibody development
Research Themes
Dr Lyons' research interests are tumour immunology of Devil Facial Tumour Disease (DFTD), immune regulation and allergy responses to pathogens and vaccine development, modulation of immunity by off-target activity of small molecule cancer therapies and the development and application of flow cytometric techniques to complex immunological questions.
He is currently a member of the Devil Facial Tumour Disease immunology group headed by Professor Greg Woods (MRIT) and collaborates with the Jack Jumper Allergy program in the RHH (Professor Simon Brown and Mr Troy Wanandy).
Collaboration
Bruce's collaborations locally include the Royal Hobart Hospital, and he collaborates with researchers at the University of South Australia, and through the Devil Immunology group researchers in Melbourne, Cambridge and Southampton.
Current projects
Currently involved in the development of immune approaches to combatting Devil Facial Tumour Disease, and analysis of T cell responses in Jack Jumper Ant Venom allergy.
Fields of Research
- Cellular immunology (320404)
- Animal immunology (310905)
- Veterinary immunology (300906)
- Immunology (320499)
- Tumour immunology (320409)
- Haematology (320102)
- Animal cell and molecular biology (310902)
- Conservation and biodiversity (410401)
- Host-parasite interactions (310407)
- Cell development, proliferation and death (310102)
- Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) (320402)
- Veterinary diagnosis and diagnostics (300904)
- Medical bacteriology (320701)
- Respiratory diseases (320103)
- Humoural immunology and immunochemistry (320405)
- Molecular targets (321108)
- Forestry management and environment (300707)
- Clinical sciences (320299)
- Aquaculture (300501)
- Zoology (310999)
- Innate immunity (320407)
- Proteomics and intermolecular interactions (excl. medical proteomics) (310109)
- Veterinary epidemiology (300905)
- Medical parasitology (320704)
- Ecosystem function (410203)
- Allergy (320401)
- Biological oceanography (370801)
- Infectious agents (310702)
- Transplantation immunology (320408)
- Bioavailability and ecotoxicology (410201)
- Behavioural ecology (310301)
- Autoimmunity (320403)
- Immunogenetics (incl. genetic immunology) (320406)
- Ecological physiology (310303)
- Veterinary bacteriology (300903)
- Population ecology (310307)
- Gene expression (incl. microarray and other genome-wide approaches) (310505)
- Animal physiological ecology (310907)
- Medical virology (320705)
- Veterinary surgery (300912)
- Animal structure and function (310911)
- Pollution and contamination (410599)
- Wildlife and habitat management (410407)
Research Objectives
- Clinical health (200199)
- Terrestrial biodiversity (180606)
- Other health (209999)
- Expanding knowledge in the biological sciences (280102)
- Expanding knowledge in the environmental sciences (280111)
- Control of pests, diseases and exotic species in terrestrial environments (180602)
- Expanding knowledge in the agricultural, food and veterinary sciences (280101)
- Diagnosis of human diseases and conditions (200101)
- Other environmental management (189999)
- Expanding knowledge in the health sciences (280112)
- Fisheries - aquaculture (100299)
- Forestry (260299)
- Efficacy of medications (200102)
- Veterinary biological preventatives (241601)
- Prevention of human diseases and conditions (200104)
- Expanding knowledge in the biomedical and clinical sciences (280103)
- Assessment and management of terrestrial ecosystems (180601)
- Control of pests, diseases and exotic species in coastal and estuarine environments (180204)
- Coastal or estuarine biodiversity (180203)
- Environmentally sustainable commercial services and tourism (110199)
- Rehabilitation or conservation of terrestrial environments (180604)
- Disease distribution and transmission (incl. surveillance and response) (200404)
Publications
Bruce has over 50 publications, many of which are in top ranked international journals. On average they have been cited around 100 times, generating an H-index of 26. His highest cited paper describes a flow based method for determining cell division history used which has been cited over 1500 times.
Bruce is currently an editorial Board member of The Journal of Immunological Methods.
Total publications
103
Journal Article
(83 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2022 | Espejo C, Patchett AL, Wilson R, Lyons AB, Woods GM, 'Challenges of an emerging disease: The evolving approach to diagnosing devil facial tumour disease', Pathogens, 11, (1) pp. 1-12. ISSN 2076-0817 (2022) [Refereed Article] DOI: 10.3390/pathogens11010027 [eCite] [Details] Co-authors: Espejo C; Patchett AL; Wilson R; Woods GM | |
| 2022 | Espejo C, Wilson R, Pye RJ, Ratcliffe JC, Ruiz-Aravena M, et al., 'Cathelicidin-3 associated with serum extracellular vesicles enables early diagnosis of a transmissible cancer', Frontiers in Immunology, 13 pp. 1-14. ISSN 1664-3224 (2022) [Refereed Article] DOI: 10.3389/fimmu.2022.858423 [eCite] [Details] Co-authors: Espejo C; Wilson R; Pye RJ; Ruiz-Aravena M; Wolfe BW; Hamede R; Woods GM | |
| 2022 | Kayigwe AN, Darby JM, Lyons AB, Patchett AL, Lisowski L, et al., 'A human adenovirus encoding IFN-γ can transduce Tasmanian devil facial tumour cells and upregulate MHC-I', Journal of General Virology, 103, (11) pp. 1-8. ISSN 0022-1317 (2022) [Refereed Article] DOI: 10.1099/jgv.0.001812 [eCite] [Details] Co-authors: Darby JM; Patchett AL; Liu G-S; Flies AS | |
| 2022 | Ong CEB, Cheng V, Siddle HV, Lyons AB, Woods GM, et al., 'Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours', Open biology, 12, (10) Article 220208. ISSN 2046-2441 (2022) [Refereed Article] DOI: 10.1098/rsob.220208 [eCite] [Details] Citations: Scopus - 1 Co-authors: Ong CEB; Woods GM; Flies AS | |
| 2021 | De Luca AJ, Lyons AB, Flies AS, 'Cytokines: Signalling improved immunotherapy?', Current Oncology Reports, 23 Article 103. ISSN 1534-6269 (2021) [Refereed Article] DOI: 10.1007/s11912-021-01095-x [eCite] [Details] Citations: Web of Science - 1 Co-authors: De Luca AJ; Flies AS | |
| 2021 | Espejo C, Wilson R, Willms E, Ruiz-Aravena M, Pye RJ, et al., 'Extracellular vesicle proteomes of two transmissible cancers of Tasmanian devils reveal tenascin-C as a serum-based differential diagnostic biomarker', Cellular and Molecular Life Sciences, 78, (23) pp. 7537-7555. ISSN 1420-682X (2021) [Refereed Article] DOI: 10.1007/s00018-021-03955-y [eCite] [Details] Citations: Scopus - 5Web of Science - 5 Co-authors: Espejo C; Wilson R; Ruiz-Aravena M; Pye RJ; Jones M; Woods GM | |
| 2021 | Ong C, Patchett AL, Darby JM, Chen J, Liu G, et al., 'NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in 3 transmissible cancers', Journal of Cancer Research and Clinical Oncology, 147, (7) pp. 1973-1991. ISSN 0171-5216 (2021) [Refereed Article] DOI: 10.1101/2020.09.06.274720 [eCite] [Details] Citations: Scopus - 6Web of Science - 6 Co-authors: Ong C; Patchett AL; Darby JM; Liu G; Woods GM; Flies AS | |
| 2021 | Patchett AL, Tovar C, Blackburn NB, Woods GM, Lyons AB, 'Mesenchymal plasticity of devil facial tumour cells during in vivo vaccine and immunotherapy trials', Immunology and Cell Biology pp. 1-13. ISSN 0818-9641 (2021) [Refereed Article] DOI: 10.1111/imcb.12451 [eCite] [Details] Citations: Scopus - 4Web of Science - 5 Co-authors: Patchett AL; Tovar C; Blackburn NB; Woods GM | |
| 2021 | Pye RJ, Darby JM, Flies AS, Fox S, Carver SS, et al., 'Post-release immune responses of Tasmanian devils vaccinated with an experimental devil facial tumour disease vaccine', Wildlife Research, 48, (8) pp. 701-712. ISSN 1035-3712 (2021) [Refereed Article] DOI: 10.1071/WR20210 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Pye RJ; Darby JM; Flies AS; Carver SS; Woods GM | |
| 2021 | Wong C, Darby JM, Murphy PR, Pinfold TL, Lennard PR, et al., 'Tasmanian devil CD28 and CTLA4 capture CD80 and CD86 from adjacent cells', Developmental and Comparative Immunology, 115 Article 103882. ISSN 0145-305X (2021) [Refereed Article] DOI: 10.1016/j.dci.2020.103882 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: Darby JM; Murphy PR; Pinfold TL; Woods GM; Flies AS | |
| 2020 | Flies AS, Darby JM, Lennard PR, Murphy PR, Ong C, et al., 'A novel system to map protein interactions reveals evolutionarily conserved immune evasion pathways on transmissible cancers', Science Advances, 6, (27) Article eaba5031. ISSN 2375-2548 (2020) [Refereed Article] DOI: 10.1126/sciadv.aba5031 [eCite] [Details] Citations: Scopus - 12Web of Science - 10 Co-authors: Flies AS; Darby JM; Lennard PR; Murphy PR; Ong C; Pinfold TL; De Luca A; Woods GM; Patchett AL | |
| 2020 | Flies AS, Flies EJ, Fox S, Gilbert A, Johnson SR, et al., 'An oral bait vaccination approach for the Tasmanian devil facial tumor diseases', Expert Review of Vaccines, 19, (1) pp. 1-10. ISSN 1476-0584 (2020) [Refereed Article] DOI: 10.1080/14760584.2020.1711058 [eCite] [Details] Citations: Scopus - 15Web of Science - 16 Co-authors: Flies AS; Flies EJ; Liu G-S; Patchett AL; Pye RJ | |
| 2020 | Lyons AB, Heinzel S, 'Chromosome social distancing and crowd control: the dual role of Ki67', Immunology and Cell Biology, 98, (9) pp. 712-714. ISSN 0818-9641 (2020) [Letter or Note in Journal] | |
| 2020 | Patchett AL, Flies AS, Lyons AB, Woods GM, 'Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii)', Cellular and Molecular Life Sciences, 77, (13) pp. 2507-2525. ISSN 1420-682X (2020) [Refereed Article] DOI: 10.1007/s00018-019-03435-4 [eCite] [Details] Citations: Scopus - 9Web of Science - 10 Co-authors: Patchett AL; Flies AS; Woods GM | |
| 2020 | Thaver S, Foa L, Richards SM, Lyons AB, Zosky GR, 'In utero exposure to diesel exhaust particles, but not silica, alters post-natal immune development and function', Chemosphere, 268 Article 1293142. ISSN 0045-6535 (2020) [Refereed Article] DOI: 10.1016/j.chemosphere.2020.129314 [eCite] [Details] Citations: Scopus - 1Web of Science - 1 Co-authors: Thaver S; Foa L; Richards SM; Zosky GR | |
| 2020 | Woods GM, Lyons AB, Bettiol SS, 'A devil of a transmissible cancer', Tropical Medicine and Infectious Disease, 5, (2) Article 50. ISSN 2414-6366 (2020) [Refereed Article] DOI: 10.3390/tropicalmed5020050 [eCite] [Details] Citations: Scopus - 3Web of Science - 4 Co-authors: Woods GM; Bettiol SS | |
| 2019 | James S, Jennings G, Kwon YM, Stammnitz M, Fraik A, et al., 'Tracing the rise of malignant cell lines: distribution, epidemiology and evolutionary interactions of two transmissible cancers in Tasmanian devils', Evolutionary Applications, 12, (9) pp. 1772-1780. ISSN 1752-4571 (2019) [Refereed Article] DOI: 10.1111/eva.12831 [eCite] [Details] Citations: Scopus - 22Web of Science - 19 Co-authors: James S; Jennings G; Comte S; Pye R; Woods G; Jones M; Hamede R | |
| 2019 | Li X, Darby J, Lyons AB, Woods GM, Korner H, 'TNF may negatively regulate phagocytosis of Devil Facial Tumour Disease cells by activated macrophages', Immunological Investigations, 48, (7) pp. 691-703. ISSN 0882-0139 (2019) [Refereed Article] DOI: 10.1080/08820139.2018.1515222 [eCite] [Details] Citations: Scopus - 3Web of Science - 5 Co-authors: Darby J; Woods GM; Korner H | |
| 2019 | Ong C, Lyons AB, Woods GM, Flies AS, 'Inducible IFN-γ expression for MHC-I upregulation in devil facial tumor cells', Frontiers in Immunology, 9 Article 3117. ISSN 1664-3224 (2019) [Refereed Article] DOI: 10.3389/fimmu.2018.03117 [eCite] [Details] Citations: Scopus - 10Web of Science - 10 Co-authors: Ong C; Woods GM; Flies AS | |
| 2019 | Patchett AL, Coorens THH, Darby J, Wilson R, McKay MJ, et al., 'Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii)', Cellular and Molecular Life Sciences, 77 pp. 1847-1858. ISSN 1420-682X (2019) [Refereed Article] DOI: 10.1007/s00018-019-03259-2 [eCite] [Details] Citations: Scopus - 16Web of Science - 15 Co-authors: Patchett AL; Darby J; Wilson R; Pye RJ; Flies AS; Woods GM; Tovar C | |
| 2019 | Thaver S, Bennett EJ, Foa L, Richards SM, Lyons AB, et al., 'Pregnancy protects against the pro-inflammatory respiratory responses induced by particulate matter exposure', Chemosphere, 225 pp. 796-802. ISSN 0045-6535 (2019) [Refereed Article] DOI: 10.1016/j.chemosphere.2019.03.088 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Thaver S; Bennett EJ; Foa L; Richards SM; Zosky GR | |
| 2019 | Wang X, Iyer A, Lyons AB, Korner H, Wei W, 'Emerging roles for G-protein coupled receptors in development and activation of macrophages', Frontiers in Immunology, 10 Article 2031. ISSN 1664-3224 (2019) [Refereed Article] DOI: 10.3389/fimmu.2019.02031 [eCite] [Details] Citations: Scopus - 14Web of Science - 15 Co-authors: Korner H | |
| 2018 | Chen L, Bennett E, Wheeler AJ, Lyons AB, Woods GM, et al., 'Maternal exposure to particulate matter alters early post-natal lung function and immune cell development', Environmental Research, 164 pp. 625-635. ISSN 0013-9351 (2018) [Refereed Article] DOI: 10.1016/j.envres.2018.03.029 [eCite] [Details] Citations: Scopus - 13Web of Science - 12 Co-authors: Chen L; Bennett E; Wheeler AJ; Woods GM; Johnston F; Zosky GR | |
| 2018 | Hu S, Marshall C, Darby J, Wei W, Lyons AB, et al., 'Absence of tumor necrosis factor supports alternative activation of macrophages in the liver after infection with Leishmania major', Frontiers in Immunology, 9 Article 1. ISSN 1664-3224 (2018) [Refereed Article] DOI: 10.3389/fimmu.2018.00001 [eCite] [Details] Citations: Scopus - 20Web of Science - 14 Co-authors: Hu S; Marshall C; Darby J; Korner H | |
| 2018 | Patchett AL, Wilson R, Charlesworth JC, Corcoran LM, Papenfuss AT, et al., 'Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells', OncoTarget, 9, (22) pp. 15895-15914. ISSN 1949-2553 (2018) [Refereed Article] DOI: 10.18632/oncotarget.24634 [eCite] [Details] Citations: Scopus - 9 Co-authors: Patchett AL; Wilson R; Charlesworth JC; Woods GM; Tovar C | |
| 2018 | Pye R, Patchett A, McLennan E, Thomson R, Carver S, et al., 'Immunization strategies producing a humoral IgG immune response against devil facial tumor disease in the majority of Tasmanian devils destined for wild release', Frontiers in Immunology, 9 Article 259. ISSN 1664-3224 (2018) [Refereed Article] DOI: 10.3389/fimmu.2018.00259 [eCite] [Details] Citations: Scopus - 23Web of Science - 25 Co-authors: Pye R; Patchett A; Carver S; Kreiss A; Woods GM | |
| 2018 | Tovar C, Patchett AL, Kim V, Wilson R, Darby J, et al., 'Heat shock proteins expressed in the marsupial Tasmanian devil are potential antigenic candidates in a vaccine against devil facial tumour disease', PLoS ONE, 13, (4) Article e0196469. ISSN 1932-6203 (2018) [Refereed Article] DOI: 10.1371/journal.pone.0196469 [eCite] [Details] Citations: Scopus - 4Web of Science - 4 Co-authors: Tovar C; Patchett AL; Wilson R; Darby J; Woods GM | |
| 2018 | Woods GM, Fox S, Flies A, Tovar CD, Jones M, et al., 'Two decades of the impact of Tasmanian Devil Facial Tumour Disease (DFTD)', Integrative and Comparative Biology, 58, (6) pp. 1043-1054. ISSN 1540-7063 (2018) [Refereed Article] DOI: 10.1093/icb/icy118 [eCite] [Details] Citations: Scopus - 7Web of Science - 6 Co-authors: Woods GM; Flies A; Tovar CD; Jones M; Hamede R; Bettiol S | |
| 2017 | Flies AS, Blackburn NB, Lyons AB, Hayball JD, Woods GM, 'Comparative analysis of immune checkpoint molecules and their potential role in the transmissible Tasmanian Devil facial tumor disease', Frontiers in Immunology, 8 Article 513. ISSN 1664-3224 (2017) [Refereed Article] DOI: 10.3389/fimmu.2017.00513 [eCite] [Details] Citations: Scopus - 12Web of Science - 14 Co-authors: Flies AS; Blackburn NB; Woods GM | |
| 2017 | Latham RD, Gell DA, Fairbairn RL, Lyons AB, Shukla SD, et al., 'An isolate of Haemophilus haemolyticus produces a bacteriocin-like substance that inhibits the growth of nontypeable Haemophilus influenzae', International Journal of Antimicrobial Agents, 49, (4) pp. 503-506. ISSN 0924-8579 (2017) [Refereed Article] DOI: 10.1016/j.ijantimicag.2016.12.010 [eCite] [Details] Citations: Scopus - 14Web of Science - 14 Co-authors: Latham RD; Gell DA; Shukla SD; Tristram SG | |
| 2017 | Li X, Lyons AB, Woods GM, Korner H, 'The absence of TNF permits myeloid Arginase 1 expression in experimental L. monocytogenes infection', Immunobiology, 222, (8-9) pp. 913-917. ISSN 0171-2985 (2017) [Refereed Article] DOI: 10.1016/j.imbio.2017.05.012 [eCite] [Details] Citations: Scopus - 9Web of Science - 7 Co-authors: Woods GM; Korner H | |
| 2017 | Patchett AL, Tovar C, Corcoran LM, Lyons AB, Woods GM, 'The toll-like receptor ligands Hiltonol® (polyICLC) and imiquimod effectively activate antigen-specific immune responses in Tasmanian devils (Sarcophilus harrisii)', Developmental and Comparative Immunology, 76 pp. 352-360. ISSN 0145-305X (2017) [Refereed Article] DOI: 10.1016/j.dci.2017.07.004 [eCite] [Details] Citations: Scopus - 11Web of Science - 12 Co-authors: Patchett AL; Tovar C; Woods GM | |
| 2017 | Tovar C, Pye RJ, Kreiss A, Cheng Y, Brown GK, et al., 'Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils', Scientific Reports, 7 Article 43827. ISSN 2045-2322 (2017) [Refereed Article] DOI: 10.1038/srep43827 [eCite] [Details] Citations: Scopus - 41Web of Science - 41 Co-authors: Tovar C; Pye RJ; Kreiss A; Brown GK; Darby J; Malley RC; Woods GM | |
| 2016 | Brown GK, Tovar C, Cooray AA, Kreiss A, Darby J, et al., 'Mitogen activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells', Immunology and Cell Biology, 94, (7) pp. 673-679. ISSN 0818-9641 (2016) [Refereed Article] DOI: 10.1038/icb.2016.38 [eCite] [Details] Citations: Scopus - 17Web of Science - 17 Co-authors: Brown GK; Tovar C; Cooray AA; Kreiss A; Darby J; Bettiol SS; Woods GM | |
| 2016 | Flies AS, Lyons AB, Corcoran LM, Papenfuss AT, Murphy JM, et al., 'PD-L1 is not constitutively expressed on Tasmanian devil facial tumor cells but is strongly upregulated in response to IFN-γ and can be expressed in the tumor microenvironment', Frontiers in Immunology, 7 Article 581. ISSN 1664-3224 (2016) [Refereed Article] DOI: 10.3389/fimmu.2016.00581 [eCite] [Details] Citations: Scopus - 29Web of Science - 29 Co-authors: Flies AS; Woods GM | |
| 2016 | Patchett AL, Darby JM, Tovar C, Lyons AB, Woods GM, 'The immunomodulatory small molecule imiquimod induces apoptosis in devil facial tumour cell lines', PL o S One, 11, (12) Article e0168068. ISSN 1932-6203 (2016) [Refereed Article] DOI: 10.1371/journal.pone.0168068 [eCite] [Details] Citations: Scopus - 11Web of Science - 10 Co-authors: Patchett AL; Darby JM; Tovar C; Woods GM | |
| 2016 | Pye RJ, Hamede R, Siddle HV, Caldwell A, Knowles GW, et al., 'Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils', Biology Letters, 12, (10) Article 20160553. ISSN 1744-9561 (2016) [Refereed Article] DOI: 10.1098/rsbl.2016.0553 [eCite] [Details] Citations: Scopus - 61Web of Science - 60 Co-authors: Pye RJ; Hamede R; Kreiss A; Jones ME; Woods GM | |
| 2015 | Kreiss A, Brown GK, Tovar C, Lyons AB, Woods GM, 'Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations', Vaccine, 33, (26) pp. 3016-3025. ISSN 0264-410X (2015) [Refereed Article] DOI: 10.1016/j.vaccine.2015.01.039 [eCite] [Details] Citations: Scopus - 40Web of Science - 36 Co-authors: Kreiss A; Brown GK; Tovar C; Woods GM | |
| 2015 | Patchett AL, Latham R, Brettingham-Moore KH, Tovar C, Lyons AB, et al., 'Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil', Developmental and Comparative Immunology, 53 pp. 123-133. ISSN 0145-305X (2015) [Refereed Article] DOI: 10.1016/j.dci.2015.07.003 [eCite] [Details] Citations: Scopus - 15Web of Science - 14 Co-authors: Patchett AL; Latham R; Brettingham-Moore KH; Tovar C; Woods GM | |
| 2015 | Pye RJ, Pemberton D, Tovar C, Tubio JM, Dun KA, et al., 'A second transmissible cancer in Tasmanian devils', Proceedings of the National Academy of Sciences, 113, (2) pp. 374-379. ISSN 0027-8424 (2015) [Refereed Article] DOI: 10.1073/pnas.1519691113 [eCite] [Details] Citations: Scopus - 140Web of Science - 138 Co-authors: Pye RJ; Tovar C; Darby J; Kreiss A; Woods GM | |
| 2015 | Woods GM, Howson LJ, Brown GK, Tovar C, Kreiss A, et al., 'Immunology of a transmissible cancer spreading among Tasmanian devils', Journal of Immunology, 195, (1) pp. 23-29. ISSN 0022-1767 (2015) [Refereed Article] DOI: 10.4049/jimmunol.1500131 [eCite] [Details] Citations: Scopus - 19Web of Science - 19 Co-authors: Woods GM; Howson LJ; Brown GK; Tovar C; Kreiss A | |
| 2012 | Blake SJ, Hughes TP, Lyons AB, 'Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A', Experimental Hematology, 40, (8) pp. 612 - 621. ISSN 0301-472X (2012) [Refereed Article] DOI: 10.1016/j.exphem.2012.04.003 [eCite] [Details] Citations: Scopus - 12Web of Science - 9 | |
| 2012 | Quah BJC, Lyons AB, Parish CR, 'The use of CFSE-like dyes for measuring lymphocyte proliferation: experimental considerations and biological variables', Mathematical Modelling of Natural Phenomena, 7, (5) pp. 53 - 64. ISSN 0973-5348 (2012) [Refereed Article] DOI: 10.1051/mmnp/20127505 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 | |
| 2011 | Brown GK, Kreiss A, Lyons AB, Woods GM, 'Natural Killer Cell Mediated Cytotoxic Responses in the Tasmanian Devil', PL o S One , 6, (9) Article e24475. ISSN 1932-6203 (2011) [Refereed Article] DOI: 10.1371/journal.pone.0024475 [eCite] [Details] Citations: Scopus - 38Web of Science - 36 Co-authors: Brown GK; Kreiss A; Woods GM | |
| 2009 | Blake SJ, Lyons AB, Hughes TP, 'Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro', Journal of Cellular and Molecular Medicine, 13, (3) pp. 599-601. ISSN 1582-1838 (2009) [Letter or Note in Journal] DOI: 10.1111/j.1582-4934.2009.00500.x [eCite] [Details] Citations: Scopus - 26 | |
| 2009 | Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, et al., 'Dasatinib inhibits recombinant viral antigen-specific murine CD4(+) and CD8(+) T-cell responses and NK-cell cytolytic activity in vitro and in vivo', Experimental Hematology, 37, (2) pp. 256-265. ISSN 0301-472X (2009) [Refereed Article] DOI: 10.1016/j.exphem.2008.09.013 [eCite] [Details] Citations: Scopus - 54Web of Science - 52 | |
| 2008 | Blake S, Hughes TP, Mayrhofer G, Lyons AB, 'The Src/Abl kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro', Clinical Immunology, 127, (3) pp. 330-339. ISSN 1521-6616 (2008) [Refereed Article] DOI: 10.1016/j.clim.2008.02.006 [eCite] [Details] Citations: Scopus - 98Web of Science - 87 | |
| 2008 | Blake S, Lyons AB, Fraser C, Hayball JD, Hughes TP, 'Dasatinib suppresses in vitro natural killer cell cytotoxicity', Blood, 111, (8) pp. 4415-4416. ISSN 0006-4971 (2008) [Refereed Article] DOI: 10.1182/blood-2008-02-138701 [eCite] [Details] Citations: Scopus - 66Web of Science - 66 | |
| 2008 | Diener KR, Moldenhauer L, Lyons AB, Brown MP, Hayball JD, 'Human Flt-3-ligand-mobilized dendritic cells require additional activation to drive effective immune responses', Experimental Hematology, 36, (1) pp. 51-60. ISSN 0301-472X (2008) [Refereed Article] DOI: 10.1016/j.exphem.2007.08.024 [eCite] [Details] Citations: Scopus - 18Web of Science - 18 | |
| 2007 | Petrovsky N, Heinzel S, Honda Y, Lyons AB, 'New-age adjuvants: friend or foe?', Biopharm International-The Applied Technologies of Biopharmaceutical Development, 20, (8) pp. A24-A33. ISSN 1542-166X (2007) [Refereed Article] Citations: Scopus - 13Web of Science - 8 | |
| 2007 | Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, et al., 'Resistance to c-KIT kinase inhibitors conferred by V654A mutation', Molecular Cancer Therapeutics, 6, (3) pp. 1159-1166. ISSN 1535-7163 (2007) [Refereed Article] DOI: 10.1158/1535-7163.MCT-06-0641 [eCite] [Details] Citations: Scopus - 70Web of Science - 73 | |
| 2006 | Lyons AB, Watkins M, Simpson CC, Muller HK, 'Modulation of lymphocyte migration to the murine spleen after macrophage phagocytosis of blood-borne particulate material', Immunological Investigations: A Journal of Molecular and Cellular Immunology, 35, (1) pp. 75-92. ISSN 0882-0139 (2006) [Refereed Article] DOI: 10.1080/08820130500496811 [eCite] [Details] Citations: Scopus - 4Web of Science - 3 Co-authors: Muller HK | |
| 2005 | Dewar AL, Cambareri AC, Zannettino ACW, Doherty KV, Hughes TP, et al., 'Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib', Blood, 105, (8) pp. 3127-3132. ISSN 0006-4971 (2005) [Refereed Article] DOI: 10.1182/blood-2004-10-3967 [eCite] [Details] Citations: Scopus - 263Web of Science - 245 | |
| 2005 | Dewar AL, Doherty KV, Hughes TP, Lyons AB, 'Imatinib inhibits the functional capacity of cultured human monocytes', Immunology and Cell Biology, 83, (1) pp. 48-56. ISSN 0818-9641 (2005) [Refereed Article] DOI: 10.1111/j.1440-1711.2004.01296.x [eCite] [Details] Citations: Scopus - 37Web of Science - 37 | |
| 2005 | Dewar AL, Zannettino ACW, Hughes TP, Lyons AB, 'Inhibition of c-fms by imatinib: expanding the spectrum of treatment', Cell Cycle, 4, (7) pp. 38-40. ISSN 1538-4101 (2005) [Refereed Article] DOI: 10.4161/cc.4.7.1788 [eCite] [Details] Citations: Scopus - 46Web of Science - 44 | |
| 2005 | Morrison RN, Lyons AB, Nowak BF, Hayball JD, 'Assessment of snapper (Pagrus auratus) natural IgM binding to bromelain treated sheep erythrocytes', Fish and Shellfish Immunology, 18, (1) pp. 91-99. ISSN 1050-4648 (2005) [Refereed Article] DOI: 10.1016/j.fsi.2004.06.006 [eCite] [Details] Citations: Scopus - 4Web of Science - 4 Co-authors: Morrison RN; Nowak BF | |
| 2005 | White DL, Saunders VA, Lyons AB, Branford S, Hughes TP, 'In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML', Blood, 106, (7) pp. 2520-2526. ISSN 0006-4971 (2005) [Refereed Article] DOI: 10.1182/blood-2005-03-1103 [eCite] [Details] Citations: Scopus - 120Web of Science - 106 | |
| 2004 | Morrison RN, Lyons AB, Nowak BF, Hayball JD, 'Snapper (Pagrus auratus) leucocyte proliferation is synergistically enhanced by simultaneous stimulation with LPS and PHA', Fish & Shellfish Immunology, 16, (3) pp. 307-319. ISSN 1050-4648 (2004) [Refereed Article] DOI: 10.1016/S1050-4648(03)00112-8 [eCite] [Details] Citations: Scopus - 16Web of Science - 12 Co-authors: Morrison RN; Nowak BF | |
| 2003 | Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB, 'Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors', Leukemia, 17, (9) pp. 1713-1721. ISSN 0887-6924 (2003) [Refereed Article] DOI: 10.1038/sj.leu.2403071 [eCite] [Details] Citations: Scopus - 53Web of Science - 49 Co-authors: Doherty KV | |
| 2002 | Wilkinson R, Lyons AB, Roberts D, Wong M-X, Bartley PA, et al., 'Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) acts as a regulator of B-cell development, B-cell antigen receptor (BCR)-mediated activation, and autoimmune disease', Blood, 100, (1) pp. 184-193. ISSN 0006-4971 (2002) [Refereed Article] DOI: 10.1182/blood-2002-01-0027 [eCite] [Details] Citations: Scopus - 99Web of Science - 84 | |
| 2001 | Dewar AL, Doherty KV, Woods GM, Lyons AB, Muller HK, 'Acquisition of immune function during the development of the Langerhans cell network in neonatal mice', Immunology, 103, (1) pp. 61-69. ISSN 0019-2805 (2001) [Refereed Article] DOI: 10.1046/j.1365-2567.2001.01221.x [eCite] [Details] Citations: Scopus - 34Web of Science - 34 Co-authors: Doherty KV; Woods GM; Muller HK | |
| 2001 | Lyons AB, Hasbold J, Hodgkin PD, 'Chapter 17 Flow cytometric analysis of cell division history using dilution of Carboxyfluorescein Diacetate Succinimidyl Ester, a stably integrated fluorescent probe', Methods in Cell Biology, 63 (Part A) pp. 375-398. ISSN 0091-679X (2001) [Refereed Article] DOI: 10.1016/S0091-679X(01)63021-8 [eCite] [Details] Citations: Web of Science - 97 | |
| 2000 | Lyons AB, 'Analysing Cell Division in vivo Using Flow Cytometric Measurement of CFSE Dye Dilution', Journal of Immunological Methods, 243, (1-2) pp. 147-154. ISSN 0022-1759 (2000) [Refereed Article] DOI: 10.1016/S0022-1759(00)00231-3 [eCite] [Details] Citations: Scopus - 570Web of Science - 540 | |
| 1999 | Lyons AB, 'Divided we stand: Tracking cell proliferation with carboxyfluorescein diacetate succinimidyl ester', Immunology and Cell Biology, 77, (6) pp. 509-515. ISSN 0818-9641 (1999) [Refereed Article] DOI: 10.1046/j.1440-1711.1999.00864.x [eCite] [Details] Citations: Scopus - 130Web of Science - 122 | |
| 1998 | Hasbold J, Lyons AB, Kehry MR, Hodgkin PD, 'Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4', European Journal of Immunology, 28, (3) pp. 1040-1051. ISSN 0014-2980 (1998) [Refereed Article] DOI: 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.3.CO;2-0 [eCite] [Details] Citations: Scopus - 169Web of Science - 163 | |
| 1998 | Lyons AB, Cooper SJ, Cole SR, Ashman LK, 'Human myeloid differentiation antigens identified by monoclonal antibodies to the myelomonocytic leukemia cell line RC-2A', Pathology, 20, (2) pp. 137-146. ISSN 0031-3025 (1998) [Refereed Article] DOI: 10.3109/00313028809066624 [eCite] [Details] Citations: Scopus - 18Web of Science - 17 | |
| 1997 | Hodgkin PD, Chin SH, Bartell G, Mamchak A, Doherty K, et al., 'The importance of efficacy and partial agonism in evaluating models of B lymphocyte activation', International Review of Immunology, 15, (1-2) pp. 101-127. ISSN 0883-0185 (1997) [Refereed Article] DOI: 10.3109/08830189709068173 [eCite] [Details] Citations: Scopus - 18 | |
| 1997 | Lyons AB, 'Pertussis toxin pretreatment alters the in vivo cell division behaviour and survival of B lymphocytes after intravenous transfer', Immunology and Cell Biology, 75, (1) pp. 7-12. ISSN 0818-9641 (1997) [Refereed Article] DOI: 10.1038/icb.1997.2 [eCite] [Details] Citations: Scopus - 18Web of Science - 16 | |
| 1996 | Bradbury MG, Doherty KV, Parish CR, Lyons AB, 'The immunosuppressive compound 2-acetyl-4-tetrahydroxybutyl imidazole inhibits the allogeneic mixed lymphocyte reaction by sequestration of a recirculating subpopulation of T cells', Immunology, 87, (1) pp. 80-85. ISSN 0019-2805 (1996) [Refereed Article] Citations: Web of Science - 8 | |
| 1996 | Fulcher DA, Lyons AB, Korn SL, Cook MC, Koleda C, et al., 'The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help', Journal of Experimental Medicine, 183, (5) pp. 2313-2328. ISSN 0022-1007 (1996) [Refereed Article] DOI: 10.1084/jem.183.5.2313 [eCite] [Details] Citations: Scopus - 232Web of Science - 218 | |
| 1996 | Hodgkin PD, Lee JH, Lyons AB, 'B cell differentiation and isotype switching is related to division cycle number', Journal of Experimental Medicine, 184, (1) pp. 277-281. ISSN 0022-1007 (1996) [Refereed Article] DOI: 10.1084/jem.184.1.277 [eCite] [Details] Citations: Scopus - 327Web of Science - 319 | |
| 1996 | Lyons AB, 'Fundamental Immunology - Book Review', Immunology and Cell Biology, 73, (1) pp. 98. ISSN 0818-9641 (1996) [Letter or Note in Journal] | |
| 1996 | Lyons AB, 'Essential Immunology - Book Review', Immunology and Cell Biology, 73, (2) pp. 186-187. ISSN 0818-9641 (1996) [Letter or Note in Journal] | |
| 1995 | Lyons AB, Parish CR, 'Are murine marginal zone macrophages the splenic white pulp analog of high endothelial venules?', European Journal of Immunology, 25, (11) pp. 3165-3172. ISSN 0014-2980 (1995) [Refereed Article] DOI: 10.1002/eji.1830251127 [eCite] [Details] Citations: Scopus - 66Web of Science - 60 | |
| 1994 | Lyons AB, Parish CR, 'Determination of lymphocyte division by flow cytometry', Journal of Immunological Methods, 171, (1) pp. 131-137. ISSN 0022-1759 (1994) [Refereed Article] DOI: 10.1016/0022-1759(94)90236-4 [eCite] [Details] Citations: Scopus - 1475Web of Science - 1413 | |
| 1993 | Deckers CL, Lyons AB, Samuel K, Sanderson A, Maddy AH, 'Alternative pathways of apoptosis induced by methylprednisolone and valinomycin analyzed by flow cytometry', Experimental Cell Research, 208, (2) pp. 362-370. ISSN 0014-4827 (1993) [Refereed Article] DOI: 10.1006/excr.1993.1257 [eCite] [Details] Citations: Scopus - 43Web of Science - 45 | |
| 1992 | Lyons AB, Samuel K, Sanderson A, Maddy AH, 'Simultaneous analysis of immunophenotype and apoptosis of murine thymocytes by single laser flow cytometry', Cytometry. Part A, 13, (8) pp. 809-821. ISSN 1552-4922 (1992) [Refereed Article] DOI: 10.1002/cyto.990130803 [eCite] [Details] Citations: Scopus - 99Web of Science - 100 | |
| 1991 | Maddy A, Lyons AB, Wu ZW, Taylor H, Sanderson A, et al., 'Discrete subpopulations, defined by CD45 isoforms, coexist within the leukaemic cells of B-chronic lymphocytic leukaemia patients', Leukemia Research, 15, (9) pp. 791-799. ISSN 0145-2126 (1991) [Refereed Article] DOI: 10.1016/0145-2126(91)90463-4 [eCite] [Details] Citations: Scopus - 4Web of Science - 4 | |
| 1990 | Lopez AF, Eglinton JM, Lyons AB, Tapley PM, To LB, et al., 'Human interleukin-3 inhibits the binding of granulocyte-macrophage colony-stimulating factor and interleukin-5 to basophils and strongly enhances their functional activity', Journal of Cellular Physiology, 145, (1) pp. 69-77. ISSN 0021-9541 (1990) [Refereed Article] DOI: 10.1002/jcp.1041450111 [eCite] [Details] Citations: Scopus - 89Web of Science - 123 | |
| 1990 | Lopez AF, Lyons AB, Eglnton JM, Park LS, Clark SC, et al., 'Specific binding of human interleukin-3 and granulocyte-macrophage colony-stimulating factor to human basophils', The Journal of Allergy and Clinical Immunology, 85, (1) pp. 99-102. ISSN 0091-6749 (1990) [Refereed Article] DOI: 10.1016/0091-6749(90)90229-W [eCite] [Details] Citations: Scopus - 30Web of Science - 34 | |
| 1988 | Cambareri AC, Ashman LK, Cole SR, Lyons AB, 'A monoclonal antibody to a human mast cell/myeloid leukaemia-specific antigen binds to normal haemopoietic progenitor cells and inhibits colony formation in vitro', Leukemia Research, 12, (11-12) pp. 929-939. ISSN 0145-2126 (1988) [Refereed Article] DOI: 10.1016/0145-2126(88)90021-5 [eCite] [Details] Citations: Scopus - 23Web of Science - 28 | |
| 1988 | Lyons AB, Ashman LK, 'The effect of recombinant cytokines on the proliferative potential and phenotype of cells of the human myelomonocytic leukaemia line, RC-2A', Leukemia Research, 12, (8) pp. 659-666. ISSN 0145-2126 (1988) [Refereed Article] DOI: 10.1016/0145-2126(88)90100-2 [eCite] [Details] Citations: Scopus - 4Web of Science - 3 | |
| 1987 | Lyons AB, Ashman LK, 'Studies on the differentiation of the human myelomonocytic cell line RC-2A in response to lymphocyte-derived factors', Leukemia Research, 11, (9) pp. 797-805. ISSN 0145-2126 (1987) [Refereed Article] DOI: 10.1016/0145-2126(87)90064-6 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 |
Chapter in Book
(3 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2019 | Lyons AB, Woods GM, 'Immune strategies to combat DFTD', Saving the Tasmanian Devil: Recovery through Science-based Management, CSIRO Publishing, C Hogg, S Fox, D Pemberton and K Belov (ed), Australia, pp. 77-84. ISBN 9781486307180 (2019) [Other Book Chapter] Co-authors: Woods GM | |
| 2013 | Lyons AB, Blake SJ, Doherty KV, 'Flow cytometric analysis of cell division by dilution of CFSE and related dyes', Current Protocols in Cytometry, John Wiley & Sons, JP Robinson et al (ed), Hoboken, NJ, pp. 9.11.1-9.11.12. ISBN 9780471142959 (2013) [Research Book Chapter] DOI: 10.1002/0471142956.cy0911s64 [eCite] [Details] Citations: Scopus - 62 Co-authors: Doherty KV | |
| 1998 | Lyons AB, Doherty KV, 'Flow cytometric analysis of cell division by dye dilution', Current Protocols in Cytometry, John Wiley and Sons, New York, J. Paul Robinson (ed), New York, pp. 9.11.1-9.11.9. ISBN 0-471-16131-4 (1998) [Research Book Chapter] DOI: 10.1002/0471142956.cy0911s27 [eCite] [Details] Citations: Scopus - 39 Co-authors: Doherty KV |
Review
(1 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2013 | Lee AYS, Eri RD, Lyons AB, Grimm MC, Korner H, 'CC chemokine ligand 20 and its cognate receptor CCR6 in mucosal T cell immunology and inflammatory bowel disease: odd couple or axis of evil?', Frontiers in Immunology, 4, (194) pp. 1-7. ISSN 1664-3224 (2013) [Substantial Review] DOI: 10.3389/fimmu.2013.00194 [eCite] [Details] Citations: Scopus - 77Web of Science - 66 Co-authors: Lee AYS; Eri RD; Korner H |
Conference Publication
(13 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2017 | Karu N, Patchett AL, Wilson R, Hamede Ross RK, Jones Menna, et al., 'Application of metabolomics and proteomics for biomarker discovery and development of therapies for the transmissible cancer, Tasmanian Devil Facial Tumour Disease', February 2nd-5th 2017, Lorne, VIC (2017) [Conference Edited] Co-authors: Karu N; Patchett AL; Wilson R; Hamede Ross RK; Jones Menna; Woods GM | |
| 2016 | Patchett A, Pinfold T, Tovar C, Lyons B, Woods G, 'Abstract B040: Imiquimod initiates tumor specific overload of the ER stress response in Tasmanian devil facial cancer cells', Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: translating science into survival, September 25-28 2016, New York, NY (2016) [Conference Extract] DOI: 10.1158/2326-6066.IMM2016-B040 [eCite] [Details] Co-authors: Patchett A; Pinfold T; Tovar C; Woods G | |
| 2016 | Patchett AL, Kalodimos G, Tovar C, Lyons AB, Woods GM, 'Analysis of toll-like receptor responses in the endangered Tasmanian devil', International Congress of Immunology, August 21-26, 2016, Melbourne, Australia (2016) [Conference Extract] DOI: 10.1002/eji.201670200 [eCite] [Details] Co-authors: Patchett AL; Kalodimos G; Tovar C; Woods GM | |
| 1999 | Lyons AB, Simpson CC, 'B lymphocyte migration to the spleen increases after Phagocytosis: A role for the chemokine BLC', 38th National Scientific Conference of the Australian Society for Medical Research, 27-29/11/1999, Leura, NSW, pp. poster 1-11. (1999) [Conference Extract] Co-authors: Simpson CC | |
| 1998 | Hughes JN, Lyons AB, 'Isotype switching in murine B1 cells and its relationship to cell division', 37th Annual Meeting of the Australian Society for Medical Research, 22-25 November, Hobart, Tasmania, pp. 70. (1998) [Conference Extract] | |
| 1998 | Lyons AB, 'Modification of the Immune Response', 37th National Scientific Conference of the Australian Society for Immunology, 22-25 November, Hobart, Tasmania, pp. Symposium 5. (1998) [Chair National Conference] | |
| 1998 | Lyons AB, Simpson CC, 'Marginal zone macrophage regulation of splenic leukocyte migration', 28th Annual meeting of the Australasian Society for Immunology, 29 November - 4 December, Melbourne, Victoria, pp. poster 7-12. (1998) [Conference Extract] Co-authors: Simpson CC | |
| 1998 | Lyons AB, Simpson CC, 'Splenic marginal zone macrophages: A multifunctional cell type of dendritic morphology which may interact with dendritic cells', Journal of Leukocyte Biology, September 23-28, Pittsburgh, USA, pp. 77. (1998) [Conference Extract] Co-authors: Simpson CC | |
| 1998 | Simpson CC, Lyons AB, 'Control of lymphocyte entry into the spleen by marginal zone macrophages', 37th Annual Meeting of the Australian Society for Medical Research, 22-25 November, Hobart, Tasmania, pp. 71. (1998) [Conference Extract] Co-authors: Simpson CC | |
| 1996 | Lee JH, Hodgkin PD, Lyons AB, 'B cell proliferation, division and differentiation in T cell dependent B cell immune reaction', Federation of the Immunological Societies of Asia-Oceania, Adelaide, pp. 110. (1996) [Conference Extract] | |
| 1995 | Doherty KV, Lyons AB, Hodgkin PD, 'CFSE - A valuable tool for investigating T cell proliferation', Australasian Flow Cytometry Group 18th Annual Meeting, Hobart, Tasmania, pp. No number. (1995) [Conference Extract] | |
| 1995 | Fulcher DA, Korn SL, Lyons AB, Parish C, Basten A, 'Deletion of autoreactive B cells - stimulation by self-antigen in the absence of T-cell help', 9th International Congress of Immunology, San Francisco, pp. 828. (1995) [Conference Extract] | |
| 1995 | Lyons AB, 'A fluorescent aggregation assay which allows the identification of the carbohydrate specificity of adhesion molescules involved in cell-cell interactions', Australasian Flow Cytometry Group 18th Annual M eeting, Hobart, Tasmania, pp. No number. (1995) [Conference Extract] |
Other Public Output
(3 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2020 | Flies AS, Patchett AL, Lyons B, Woods G, 'We developed tools to study cancer in Tasmanian devils. They could help fight disease in humans', The Conversation, online, 2 July 2020 (2020) [Magazine Article] Co-authors: Flies AS; Patchett AL; Woods G | |
| 1998 | Lyons AB, 'Medical Research Week', Tastalk, Tasmanian branch - AMA, Hobart, October (1998) [Internal Newsletter] | |
| 1998 | Lyons AB, 'A sound investment in our future health', The Star, Hobart, June 4 (1998) [Newspaper Article] |
Grants & Funding
Funding Summary
Number of grants
40
Total funding
Projects
- Description
- This project will assess lead exposure in Tasmanian devils inhabiting forestry plantations, a land use heavily reliant on macropod culling. This will involve a two-pronged approach: 1) assessment of the effect of seasonal culling events on short-term exposure using blood lead levels, and 2) estimate long-term exposure in the same animals, using hair samples and an innovative lead analysis tool, x-ray fluorescence. This project is done in accordance with AEC permit number 23211. Evie Jones was competency assessed in all veterinary procedures by Dr Alex Kreiss in August 2021 and will be re-assessed in August 2022.
- Funding
- Paddy Pallin Foundation ($10,000)
- Scheme
- Grant-Science
- Administered By
- University of Tasmania
- Research Team
- Hamede Ross RK; Hampton J; Jones ME; Lyons AB; Koch A; Mann D; Jones EM
- Year
- 2022
- Description
- The Tasmanian devil has been decimated in the wild due to the transmissible cancer known as Devil Facial Tumour Disease (DFTD). The main aim of this project is the development of an early diagnostic test based on extracellular vesicle approaches to detect infected devils with DFTD before clinical presentation of tumours.
- Funding
- University of Tasmania Foundation Inc ($15,000)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Lyons AB; Espejo CI; Peck S; Jones ME; Pinfold T
- Year
- 2021
- Description
- The two genetically independent transmissible cancers affecting Tasmanian devils (DFT1 and DFT2) can be only differentially diagnosed once tumours have appeared. However, DFT1 and DFT2 cannot be diagnosed when tumours are not available to sample. This project will validate a differential diagnosis biomarker for DFTD in serum samples and will explore whether it can serve as an early DFT2 biomarker.
- Funding
- University of Tasmania Foundation Inc ($50,000)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Lyons AB; Espejo CI; Hamede Ross RK; Wilson RR; Patchett AL
- Year
- 2021
- Description
- I aim to identify the distribution and abundance of devils and quolls in forestry plantation landscapes, the effect of these landscapes on individual health, and the fine-scale response of devils to forest harvesting practices. The synthesis of these results will provide a comprehensive understanding of how native Tasmanian carnivores respond to plantation forestry operations at multiple scales - large and fine, spatial and longitudinal. The results will allow me to provide science-based recommendations to forestry groups to enhance conservation of these carnivores within plantation landscapes.
- Funding
- Forest Practices Authority ($1,960)
- Scheme
- Donation - Individual
- Administered By
- University of Tasmania
- Research Team
- Hamede Ross RK; Jones ME; Lyons AB; Jones EM
- Year
- 2020
- Description
- One off Donation received from Forest Practices Authority towards PhD project. I aim to identify the distribution and abundance of devils and quolls in forestry plantation landscapes, the effect of these landscapes on individual health, and the fine-scale response of devils to forest harvesting practices. The synthesis of these results will provide a comprehensive understanding of how native Tasmanian carnivores respond to plantation forestry operations at multiple scales - large and fine, spatial and longitudinal. The results will allow me to provide science-based recommendations to forestry groups to enhance conservation of these carnivores within plantation landscapes.
- Funding
- Donation via University of Tasmania Foundation ($2,450)
- Scheme
- Donation - Individual
- Administered By
- University of Tasmania
- Research Team
- Hamede Ross RK; Jones ME; Lyons AB; Jones EM
- Year
- 2020
- Description
- PhD project: Evie JonesTo identify the distribution and abundance of devils and quolls in forestry plantation landscapes, the effect of these landscapes on individual health, and the fine-scale response of devils to forest harvesting practices. The synthesis of these results will provide a comprehensive understanding of how native Tasmanian carnivores respond to plantation forestry operations at multiple scales - large and fine, spatial and longitudinal, providing science-based recommendations to forestry groups to enhance conservation of these carnivores within plantation landscapes.
- Funding
- Holsworth Wildlife Research Endowment ($7,375)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Hamede Ross RK; Jones ME; Lyons AB
- Period
- 2020 - 2022
- Description
- This project aims to develop a devil facial tumour (DFT) disease vaccine based on a highly-successful rabies virus vaccine platform. The bait-vaccine approach works by incorporating tumour antigens (i.e. proteins or peptides) into a non-replicating adenovirus in the laboratory, and then packaging the virus into 'blister packs' that are distributed in the landscape for target animals (i.e. devils) to eat. The virus then infects the animal when the blister pack breaks open in the animal's mouth and induces an immune response against the virus and the tumour antigens. To achieve our bait-vaccine goals we need to bring together teams diverse sets of skills, including but not limited to immunologists, geneticists, and ecologists. This research complements our existing devil immunology research but will require the cross-disciplinary expertise of Rick Liu's genetic engineering team to develop the adenovirus-based vaccine platform. The genetic engineering team will harness existing collaborations with the Children's Medical Research Institute to produce the adenoviruses for the devil team's pilot studies. Long-term development of this project will include veterinarians and ecologists from the School of Natural Sciences and DPIPWE. We will apply for funding from the Save the Tasmanian Devil Appeal to develop the field-based aspects of the project. This is likely the only approach that has the potential to eradicate DFT disease from Tasmania.
- Funding
- University of Tasmania ($9,952)
- Scheme
- Grant-Research Enhancement Program
- Administered By
- University of Tasmania
- Research Team
- Flies AS; Liu R; Lyons AB; Patchett AL; Pye RJ
- Year
- 2019
- Description
- This project will investigate cell-mediated immunity in wild devils and its relationship with devil facial tumour disease (DFTD). In addition, this project will research small vesicles called exosomes secreted by DFT cells as a potential biomarker for DFTD diagnosis and prognosis.
- Funding
- National Geographic Society ($8,698)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Lyons AB; Espejo CI
- Year
- 2019
- Description
- This project will use sequencing to generate gene profiles of immune cells in healthy and diseased Tasmanian devils. These datasets will enable identification of immune cell subsets in the Tasmanian devil, and will be mined to detect changes to immune function in diseased devils.
- Funding
- University of Tasmania ($12,951)
- Scheme
- Grant-Research Enhancement Program
- Administered By
- University of Tasmania
- Research Team
- Patchett AL; Lyons AB; Flies AS
- Year
- 2019
- Description
- Tasmanian devil numbers have declined by 80% over the last 23 years due to the emergence of transmissible cancers called devil facial tumour (DFT) disease. To protect the Tasmanian devil, conservation strategies are required to rebuild devil populations in the wild. We propose developing an oral bait vaccine that will be eaten by wild devils to provide immunity to DFTs. Unlike traditional injected vaccines, bait vaccines are dropped into habitat using bait despensers, thus eliminating the need to capture devils for vaccination. This will allow wide-spread vaccination of devils across Tasmania, thus protecting the entire population from DFTs.
- Funding
- CSIRO-Commonwealth Scientific & Industrial Research Organisation ($100)
- Scheme
- Scholarship-ON Prime
- Administered By
- University of Tasmania
- Research Team
- Patchett AL; Flies AS; Lyons AB; Espejo CI
- Year
- 2019
- Description
- Purchase of a 5 laser Cytoflex LX flow cytometer. This equipment has the ability to examine the full range of fluorescent proteins used in advanced molecular biology and in complex analyses which are not possible using our current instruments.
- Funding
- University of Tasmania ($100,000)
- Scheme
- null
- Administered By
- University of Tasmania
- Research Team
- Flies AS; Lyons AB; Pinfold T
- Year
- 2019
- Description
- The current DFTD vaccine can induce anti-DFTD immune responses, but the scalability and efficacy of the vaccine needs to be improved to deliver a broad conservation impact. This proposal builds on ongoing vaccine research to identify tumour-associated antigens that can be used to produce a highly replicable and scalable DFTD vaccine.
- Funding
- University of Tasmania Foundation Inc ($34,256)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Flies AS; Woods GM; Lyons AB; Wilson RR
- Period
- 2018 - 2019
- Description
- This project is focused in investigating the cell-mediated immunity in wild devils and its relation to DFTD, contributing complementary and relevant information to the current efforts to the vaccine development against DFTD.
- Funding
- Holsworth Wildlife Research Endowment ($17,609)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Lyons AB; Woods GM; Espejo CI
- Period
- 2018 - 2020
- Description
- The Save the Tasmanian Devil Program's wild devil recovery project saw the release of 33 devils in 2016. All were immunised against DFTD in a clinical trial by the Menzies Institute for Medical Research. Ongoing monitoring will evaluate the duration of the immunisation responses, and the impact of released devils on the incumbent population.
- Funding
- University of Tasmania Foundation Inc ($19,999)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Pye RJ; Fox S; Lyons AB
- Period
- 2018 - 2019
- Description
- This project will use sequencing to identify key cell subsets and molecular functions in devil facial tumour disease (DFTD) that are associated with tumour survival and regression. This information will be harnessed for improvement of candidate DFTD therapies and vaccines in the Tasmanian devil.
- Funding
- University of Tasmania Foundation Inc ($32,775)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Patchett AL; Lyons AB; Tovar Lopez CD
- Year
- 2018
- Funding
- Australian Research Council ($303,931)
- Scheme
- Grant-Discovery Projects
- Administered By
- University of Tasmania
- Research Team
- Woods GM; Lyons AB; Corcoran L; Hayball J; Murphy J; Flies AS
- Period
- 2018 - 2020
- Grant Reference
- DP180100520
- Description
- We have developed a system that allows us to switch genes on/off in devil facial tumour (DFT) cells. The DFT-Off cells have the potential to be used as a live-attenuated vaccine, which generally perform better than killed vaccines, that provides long-term protection against both forms of DFT disease (DFTD).
- Funding
- University of Tasmania Foundation Inc ($35,000)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Flies AS; Woods GM; Lyons AB
- Period
- 2017 - 2018
- Description
- Checkpoint molecule blockade immunotherapy (e.g. PD-1 monoclonal antibody) has achieved unprecedented success in treating several types of cancer, and ITIM and ITSM signalling play a key role in these treatment approaches. The cancer immunotherapy market reached $16.9 billion in 2015 and is expected to grow to $75 billion by 2022 (GBI 2016). This has greatly improved patient outcomes, but the cost to a single patient can exceed $100,000. The research proposed here has the potential to discover many new drug targets. Importantly, the targets are short peptide sequences, which open the door to using small molecule compounds instead that can be produced and formulated at a significantly lower cost than protein-based therapies. This will benefit cancer patients by reducing the cost for treatment and simultaneously help UTAS enter the rapidly expanding cancer immunotherapy market.
- Funding
- University of Tasmania Foundation Inc ($36,155)
- Scheme
- Grant-Cancer Research
- Administered By
- University of Tasmania
- Research Team
- Flies AS; Guven N; Blackburn NR; Lyons AB
- Year
- 2017
- Description
- To successfully vaccinate Tasmanian devils against DFTD, a particular form of response known as cell mediated immunity is needed. This project will test the ability of two distinct approaches to enhance cell mediated immune responses against DFTD.
- Funding
- University of Tasmania Foundation Inc ($32,304)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Lyons AB; Patchett AL; Woods GM
- Period
- 2017 - 2018
- Description
- Natural Killer (NK) cells have a major role in the first line of defence against cancer. This project will investigate the presence and function of NK cells in the Tasmanian devil. The ultimate goal is to determine if NK cells are involved in the rejection of DFTD tumours.
- Funding
- University of Tasmania Foundation Inc ($26,487)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Woods GM; Lyons AB; Flies AS
- Year
- 2017
- Description
- To develop a vaccine against Devil Facial Tumour Disease
- Funding
- University of Tasmania Foundation Inc ($537,451)
- Scheme
- Donation - Individual
- Administered By
- University of Tasmania
- Research Team
- Woods GM; Lyons AB
- Period
- 2016 - 2019
- Description
- Immunotherapeutics targeting PD-1 and CTLA4 have shown unprecedented success in treating human cancers. Surprisingly, little is known to date on the potential for translating these human immunotherapy approaches into cancer treatments for veterinary medicine. The Tasmanian devil facial tumours (DFTs) and canine transmissible venereal tumour (CTVT) provide unique opportunities to assess immunotherapeutic treatment regimens for two naturally occurring tumours. Our ongoing work on the DFT has already developed ten anti-PD-1, nine anti-PD-L1 (aka B7-H1), and four anti-CTLA4 monoclonal antibodies (mAbs) that are highly specific for devil proteins. We have developed a system that can be used to rapidly generate new mAbs against additional target proteins. Importantly, this system can be readily applied to the production of antibodies that target proteins in other species. We have already begun cloning target genes in dogs, and will begin production of recombinant dog proteins, cell lines, and mAbs in 2016. The devil immunology group will develop dog-specific mAbs, and perform in vitro testing functional testing of the mAbs. The first batch of antibodies for PETization will be delivered to Nexvet in January, 2017. The initial functional testing of the antibodies performed by the devil immunology team will generate vital preliminary data to support planned ARC Linkage Project application in 2016-2017 in order to leverage funds for ongoing collaborative research. Establishing a solid connection between Nexvet and the devil immunology team prior to submission of the ARC Linkage Project application will greatly increase the probability receiving a Linkage Project award and leveraging funds. This research could help save an iconic Australian animal from extinction, develop immunotherapeutics to improve and extend the lives of pets around the world, and help to drive an emerging market for pharmaceuticals for pets.
- Funding
- Department of Industry, Science, Energy and Resources ($50,000); Nexvet Australia Pty Ltd ($90,000)
- Scheme
- Contract Research
- Administered By
- University of Tasmania
- Research Team
- Flies AS; Woods GM; Lyons AB; Hayball J
- Period
- 2016 - 2017
- Description
- We have discovered that our current vaccine approach of using interferon-gamma (IFNg) to make the DFTD tumour cells visible to the devil immune system also induces upregulation of molecules that inhibit anti-tumour immune responses. We are now modifying the vaccine to counteract the effects of the inhibitory molecules.
- Funding
- University of Tasmania Foundation Inc ($35,000)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Flies AS; Woods GM; Lyons AB
- Year
- 2016
- Description
- Monitoring the immune response of vaccinated Tasmanian devils requires analysis of cell mediated immunity .The current assays we use demonstrate killing of DFTD cells but fail to reveal cytotoxic cell activation and themeans of cell death. We plan incorporate a new assay that employs fluorescent in situ hybridisation andbranched DNA amplification technique for simultaneous measurement of RNA transcripts in single cells usingflow cytometry. The advantages of the proposed assay is that it provides a rapid and biologically relevantanalysis of fresh blood samples taken from Tasmanian devils and measures the activity level of these cellsequivalent to when they were in circulation. This will determine if cytotoxic cells are activated to induce targetcell death. We will be able to analyse key gene expression markers for activation such as IFN-gamma andLAMP-I.
- Funding
- University of Tasmania Foundation Inc ($34,999)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Pinfold T; Bettiol SS; Woods GM; Lyons AB
- Year
- 2016
- Description
- This project is aimed at refining our immunisation procedure that stimulates the devil's immune system to recognise and kill DFTD tumour cells.
- Funding
- University of Tasmania Foundation Inc ($139,262)
- Scheme
- Grant - Institutional
- Administered By
- University of Tasmania
- Research Team
- Lyons AB; Kreiss A; Woods GM; Pye RJ; Flies A
- Period
- 2015 - 2021
- Description
- DFTD should be recognised and rejected by the Tasmanian devil's immune system as a foreign graft, but it appears to be invisible. This project aims to discover if re-expression of MHC molecules allows DFTD cells to be recognised as an allograft and ultimately be killed by the devil immune system. In vitro cell culture techniques and flow cytometry will be used to examine responses. The demonstration that tumour cells can be recognized by cytotoxic T cells will aid the design of immune based strategies for prevention and therapy.
- Funding
- University of Tasmania Foundation Inc ($28,000)
- Scheme
- Grant-Dr Eric Guiler Tasmanian Devil Research Gran
- Administered By
- University of Tasmania
- Research Team
- Lyons AB; Woods GM
- Year
- 2014
- Description
- Allergy to Jack Jumper venom is an acute medical emergency which potentially affects >1% of Tasmanians. Desensitisation by venom immunisation therapy (VIT) protects against severe reactions, but the precise mechanism has not been elucidated. This project seeks to understand how immune cells are 're-educated' to prevent life-threatening allergy.
- Funding
- Royal Hobart Hospital Research Foundation ($5,000)
- Scheme
- Grant-Starter
- Administered By
- University of Tasmania
- Research Team
- Lyons AB; Wanandy ST; Doherty KV; Brown SG; Wiese MD
- Year
- 2014
- Description
- Tasmanian devils only exist in Tasmania and Devil Facial Tumour Disease, an infectious cancer, could cause the extinction of the Tasmanian devil. This project will determine if Devil Facial Tumour Disease reduces the effectiveness of the devil's immune system and test if activated immune cells can protect against this disease.
- Funding
- Australian Research Council ($380,000)
- Scheme
- Grant-Discovery Projects
- Administered By
- University of Tasmania
- Research Team
- Woods GM; Lyons AB; Corcoran L
- Period
- 2013 - 2015
- Grant Reference
- DP130100715
- Description
- The iconic Tasmanian devil is threatened with extinction from a uniformly fatal transmissible facial cancer. This project builds on existing research on the cancer cells that can be recognised by the devil immune system. It will develop and test a vaccine against the tumour, which will ultimately protect devils in the wild.
- Funding
- Australian Research Council ($412,912)
- Scheme
- Grant-Linkage Projects Round 1
- Administered By
- University of Tasmania
- Research Team
- Woods GM; Lyons AB
- Period
- 2013 - 2015
- Grant Reference
- LP130100218
- Funding
- University of Tasmania Foundation Inc ($29,736)
- Scheme
- Award-Eric Guiler Foundation
- Administered By
- University of Tasmania
- Research Team
- Kreiss A; Woods GM; Lyons AB; Tovar Lopez CD
- Year
- 2012
- Funding
- University of Tasmania ($1,005)
- Scheme
- Grant-Conference Support Scheme
- Administered By
- University of Tasmania
- Research Team
- Lyons AB
- Year
- 2011
- Funding
- University of Tasmania ($15,000)
- Scheme
- Grant-Supplementary
- Administered By
- University of Tasmania
- Research Team
- Lyons AB
- Year
- 1999
- Funding
- Clifford Craig Foundation ($2,500)
- Scheme
- Grant-Collaborative
- Administered By
- University of Tasmania
- Research Team
- Lyons AB
- Year
- 1999
- Funding
- National Health & Medical Research Council ($144,735)
- Scheme
- Grant-MRC Project
- Administered By
- University of Tasmania
- Research Team
- Lyons AB; Muller HK
- Period
- 1998 - 2000
- Grant Reference
- 981546
- Funding
- Clifford Craig Foundation ($7,520)
- Scheme
- Grant-Collaborative
- Administered By
- University of Tasmania
- Research Team
- Lyons AB
- Year
- 1998
- Funding
- University of Tasmania ($15,000)
- Scheme
- Grant-Supplementary
- Administered By
- University of Tasmania
- Research Team
- Lyons AB
- Year
- 1997
- Funding
- National Health & Medical Research Council ($20,000)
- Scheme
- Grant-Equipment
- Administered By
- University of Tasmania
- Research Team
- Woods GM; Kirov SM; Lyons AB; Muller HK
- Year
- 1997
- Grant Reference
- 971378
- Funding
- Clive & Vera Ramaciotti Foundation ($5,000)
- Scheme
- Grant-Establishment
- Administered By
- University of Tasmania
- Research Team
- Lyons AB
- Year
- 1996
- Funding
- University of Tasmania ($10,000)
- Scheme
- Grant-Supplementary
- Administered By
- University of Tasmania
- Research Team
- Lyons AB
- Year
- 1996
- Funding
- National Health & Medical Research Council ($10,000)
- Scheme
- Grant-Equipment
- Administered By
- University of Tasmania
- Research Team
- Woods GM; Dandie GW; Lyons AB; Muller HK
- Year
- 1996
- Grant Reference
- 961451
Research Supervision
Bruce has 5 past HDR completions, and currently supervises or co-supervises 5 PhD students at the University of Tasmania.
Current
1
Completed
12
Current
| Degree | Title | Commenced |
|---|---|---|
| PhD | Identification of Devil Facial Tumour Antigens for Vaccine Development | 2019 |
Completed
| Degree | Title | Completed |
|---|---|---|
| PhD | The Response of Marsupial Carnivores to Production Forest Landscapes and Operations Candidate: Evie Maree Jones | 2023 |
| Masters | Development of Synthetic Immunological Tools for Tasmanian Devil Research Candidate: Alana Jane De Luca | 2022 |
| PhD | Manipulation of Devil Facial Tumour Cells to Enhance Immunogenicity Candidate: Chrissie Ee Been Ong | 2022 |
| PhD | Novel Approach to Treat Viral Pneumonia Candidate: Pratikshya Pandey | 2022 |
| PhD | Immunological Tools and Early Diagnostic Approaches to Monitor the Effects of Devil Facial Tumour Disease on Wild Tasmanian Devils Candidate: Camila Ignacia Espejo Benavides | 2021 |
| PhD | The Early Life Effects of Maternal Exposure to Particulate Matter Candidate: Santon Thaver | 2021 |
| PhD | Role of TNF in the Regulation of the Innate Immune Response in Leishmaniasis Candidate: Shanshan Hu | 2018 |
| PhD | An Investigation of the Inhibition of Non-typeable Haemophilus influenzae, by Substances Secreted by Haemophilus haemolyticus Candidate: Roger Declan Latham | 2018 |
| PhD | Redefining the Role of Tumour Necrosis Factor in Macrophage Differentiation and Effector Function in Bacterial and Tumour Defences Candidate: Xinying Li | 2018 |
| PhD | Toll-Like Receptors in the Endangered Tasmanian Devil and Devil Facial Tumour Disease Candidate: Amanda Louise Patchett | 2018 |
| PhD | Immune Recognition of Devil Facial Tumour Disease by the Tasmanian Devil Candidate: Ruth Jacqueline Pye | 2017 |
| PhD | Manipulating the Immune Response of Tasmanian Devils to Target Devil Facial Tumour Disease Candidate: Gabriella Kathleen Brown | 2013 |